Argos Therapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

DURHAM, N.C., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeff Abbey, president and chief executive officer, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at 3:20 p.m. Eastern Time. The conference will be held at the New York Palace Hotel in New York, NY.

A live audio webcast of the presentation can be accessed via the Investors section of the Company's website at www.argostherapeutics.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 14 days following the presentation.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company also plans to report data from its phase 2b clinical trial of AGS-004 for the treatment of HIV in the third quarter of 2014. AGS-004 is currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

CONTACT: Media: Jen Ringler Berry & Company Public Relations jringler@berrypr.com (212) 253-8881 Investors: Angeli Kolhatkar Burns McClellan akolhatkar@burnsmc.com (212) 213-0006

Source:Argos Therapeutics, Inc.